Paper41345972
Integrated bulk and single-cell transcriptomics to develop an efferocytosis-related prognostic model for lung adenocarcinoma and validate the key gene LDHA.
Zhang W and 8 others. Eur J Med Res, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Integrated bulk and single-cell transcriptomics to develop an efferocytosis-related prognostic model for lung adenocarcinoma and validate the key gene LDHA. Papers, record 41345972. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41345972
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Integrated bulk and single-cell transcriptomics to develop an efferocytosis-related prognostic model for lung adenocarcinoma and validate the key gene LDHA.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma of Lung | Major topic |
| Lung Neoplasms | Major topic |
| Transcriptome | Major topic |
| Phagocytosis | Major topic |
| L-Lactate Dehydrogenase | Major topic |
| Humans | |
| Prognosis | |
| Single-Cell Analysis | |
| Lactate Dehydrogenase 5 | |
| Gene Expression Profiling | |
| Biomarkers, Tumor | |
| Gene Expression Regulation, Neoplastic | |
| Efferocytosis |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| No. LH2022H112; No. LSFGG-2024095 | Natural Science Foundation of Heilongjiang Province; Joint Guidance Project of the Science and Technology Plan of Qiqihar City | PubMed |
Source PubMed
References72
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 2 | 32927274 | Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma. | EBioMedicine | 2020 | https://conductscience.org/library/papers/32927274 | PubMed |
| 3 | 39788719 | Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control. | Gut | 2025 | https://conductscience.org/library/papers/39788719 | PubMed |
| 4 | 34292673 | Tumor Associated Macrophages and TAMs-Based Anti-Tumor Nanomedicines. | Adv Healthc Mater | 2021 | https://conductscience.org/library/papers/34292673 | PubMed |
| 5 | 30464343 | Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release. | Nature | 2018 | https://conductscience.org/library/papers/30464343 | PubMed |
| 6 | 36792751 | A timeline of tumour-associated macrophage biology. | Nat Rev Cancer | 2023 | https://conductscience.org/library/papers/36792751 | PubMed |
| 7 | 37649478 | Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects. | Front Immunol | 2023 | https://conductscience.org/library/papers/37649478 | PubMed |
| 8 | 31350295 | The Tumor Microenvironment Innately Modulates Cancer Progression. | Cancer Res | 2019 | https://conductscience.org/library/papers/31350295 | PubMed |
| 9 | 33331847 | Tumor Mutation Burden and Cancer Treatment. | JAMA Oncol | 2021 | https://conductscience.org/library/papers/33331847 | PubMed |
| 10 | 39987127 | Integration of single-cell and bulk RNA sequencing to identify a distinct tumor stem cells and construct a novel prognostic signature for evaluating prognosis and immunotherapy in LUAD. | J Transl Med | 2025 | https://conductscience.org/library/papers/39987127 | PubMed |
| 11 | 38733825 | Silencing BMAL1 promotes M1/M2 polarization through the LDHA/lactate axis to promote GBM sensitivity to bevacizumab. | Int Immunopharmacol | 2024 | https://conductscience.org/library/papers/38733825 | PubMed |
| 12 | 20808728 | Regularization Paths for Generalized Linear Models via Coordinate Descent. | J Stat Softw | 2010 | https://conductscience.org/library/papers/20808728 | PubMed |
| 13 | 37576862 | Cancer stem cells in brain tumors: From origin to clinical implications. | MedComm (2020) | 2023 | https://conductscience.org/library/papers/37576862 | PubMed |
| 14 | 21376230 | Hallmarks of cancer: the next generation. | Cell | 2011 | https://conductscience.org/library/papers/21376230 | PubMed |
| 15 | 37670970 | NOX4-derived ROS Regulates Aerobic Glycolysis of Breast Cancer through YAP Pathway. | J Cancer | 2023 | https://conductscience.org/library/papers/37670970 | PubMed |
| 16 | 37686110 | MiRNAs in Lung Adenocarcinoma: Role, Diagnosis, Prognosis, and Therapy. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37686110 | PubMed |
| 17 | 35352671 | EGFR Inhibitor CL-387785 Suppresses the Progression of Lung Adenocarcinoma. | Curr Mol Pharmacol | 2023 | https://conductscience.org/library/papers/35352671 | PubMed |
| 18 | 35650427 | Drugging the efferocytosis process: concepts and opportunities. | Nat Rev Drug Discov | 2022 | https://conductscience.org/library/papers/35650427 | PubMed |
| 19 | 30275043 | Roles of the immune system in cancer: from tumor initiation to metastatic progression. | Genes Dev | 2018 | https://conductscience.org/library/papers/30275043 | PubMed |
| 20 | 40672961 | Prediction and immune landscape study of potentially key autophagy-related biomarkers in preeclampsia with gestational diabetes mellitus. | Front Immunol | 2025 | https://conductscience.org/library/papers/40672961 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42899246 | The Efferocytosis-Driven Macrophage Polarization: A Concerto in the Tumor Immunosuppressive Microenvironment. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42899246 | PubMed |
| 42734102 | Spatial and Temporal Heterogeneity of Macrophage Efferocytosis in Tumors: Emerging Implications for Immunotherapy Biomarkers and Therapeutic Timing. | Cancer Med | 2026 | https://conductscience.org/library/papers/42734102 | PubMed |
| 42434863 | LDHA, BIK, and CNIH4 Are Diagnostic Markers of Endoplasmic Reticulum Stress in Lung Cancer Comorbid With Sepsis: Integrating Machine Learning and Single-Cell Analysis of Immune Signaling. | Mediators Inflamm | 2026 | https://conductscience.org/library/papers/42434863 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| LDHA | 3939 | PubTator's text mining | https://conductscience.org/library/genes/3939 | NCBI Gene |
| SPP1 | 6696 | PubTator's text mining | https://conductscience.org/library/genes/6696 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41345972
GET https://conductscience.org/api/papers/v1/41345972/references?page=2